Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
This randomized phase II trial studies how well obinutuzumab with or without PI3K-delta
inhibitor TGR-1202, lenalidomide, or combination chemotherapy work in treating patients with
grade I-IIIa follicular lymphoma that has come back or does not respond to treatment.
Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells
to grow and spread. PI3K-delta inhibitor TGR-1202 may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Biological therapies, such as
lenalidomide, use substances made from living organisms that may stimulate or suppress the
immune system in different ways and stop cancer cells from growing. Drugs used in
chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and
prednisone, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. It is not yet
known whether giving obinutuzumab with or without PI3K-delta inhibitor TGR-1202,
lenalidomide, or combination chemotherapy will work better in treating patients with grade
I-IIIa follicular lymphoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.